TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17222813

Group type: EXPERIMENTAL
Intervention: Enalapril (E(+): 10 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Losartan (L(+): 50 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Enalapril + Losartan (E(+)L(+): 10 mg/day + 50 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No medication (E(-)L(-))
Number of subjects: 64
Study: 15563440

Group type: EXPERIMENTAL
Intervention: 40 mg/day iron supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11740293

Group type: EXPERIMENTAL
Intervention: Patients with PAD
Number of subjects: 14
Study: 9241004

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bupropion 100 mg three times daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8347437

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg od)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Cetirizine (10 mg od)
Number of subjects: 158
Study: 3521559

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg, single oral dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (administered for eight days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31625041

Group type: EXPERIMENTAL
Intervention: Systems-level approach with MA-delivered health coaching sessions
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard health coaching procedures (Control)
Number of subjects: 119
Study: 30047223

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) insulin pump delivery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Threshold-low-glucose-suspend (TLGS) insulin pump delivery
Number of subjects: 24
Study: 29070640

Group type: EXPERIMENTAL
Intervention: BETSILE programme
Number of subjects: 288

Group type: COMPARATOR
Intervention: SILE programme
Number of subjects: 288
Study: 26905985

Group type: EXPERIMENTAL
Intervention: 2 g of magnesium sulphate intravenously
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study: 24071760

Group type: EXPERIMENTAL
Intervention: Telephone counseling (once a week) and text messaging (five times a week) using stages of change
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional telephone counseling (once a month)
Number of subjects: 48
Study: 21862166

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 6005

Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 6005

Group type: EXPERIMENTAL
Intervention: Metformin and Sulphonylureas
Number of subjects: 6005
Study: 18972927

Group type: EXPERIMENTAL
Intervention: Urinating immediately before DRE
Number of subjects: 200
Study: 17124817

Group type: EXPERIMENTAL
Intervention: Wound bed preparation
Number of subjects: 0
Study: 14531593

Group type: EXPERIMENTAL
Intervention: Topical application of 1.5 mol/L aqueous solution of CaCl2 followed by 1.0 mol/L aqueous K3PO4
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical application of 1.0 mol/L aqueous solution of KCl followed by distilled water
Number of subjects: 30
Study: 11003455

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg/day for 3 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8840843

Group type: EXPERIMENTAL
Intervention: Fish oils (5.4 g n‐3 fatty acids)
Number of subjects: 814

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (30 mg SC BID)
Number of subjects: 814

Group type: COMPARATOR
Intervention: Control
Number of subjects: 814
Study: 1309968

Group type: EXPERIMENTAL
Intervention: 12 mg of ASA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 27
Study: 6851195

Group type: EXPERIMENTAL
Intervention: Oestrogen-progestagen oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Essential hypertension (control group)
Number of subjects: 0
Study: 30777514

Group type: EXPERIMENTAL
Intervention: Low probability of outcome following a predicting stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: High probability of outcome following a predicting stimulus
Number of subjects: 0
Study: 29288740

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted mindfulness smoking cessation intervention with contingency management (SMI-CM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Enhanced standard treatment plus non-contingent contingency management (EST)
Number of subjects: 8
Study: 26332293

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Crossover from rhythm to rate control
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Crossover from rate to rhythm control
Number of subjects: 1376
Study: 23964146

Group type: EXPERIMENTAL
Intervention: Rikkunshito alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rikkunshito plus PPI (lansoprazole)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rikkunshito
Number of subjects: 22
Study: 21746974

Group type: EXPERIMENTAL
Intervention: Early treatment (ET) for type 1 ROP
Number of subjects: 317

Group type: COMPARATOR
Intervention: Conventional management (CM) for type 1 ROP
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Early treatment (ET) for type 2 ROP
Number of subjects: 317

Group type: COMPARATOR
Intervention: Conventional management (CM) for type 2 ROP
Number of subjects: 317

Group type: COMPARATOR
Intervention: Overall ET vs CM for high-risk prethreshold ROP
Number of subjects: 317
Study: 19282374

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 34
Study: 16961669

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural stress management programme
Number of subjects: 159

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 159
Study: 15717708

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study: 11762556

Group type: EXPERIMENTAL
Intervention: Omapatrilat 10 mg on days 6 to 10 and 25 mg on days 11 to 15 with furosemide 20 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo with furosemide 20 mg
Number of subjects: 26
Study: 8273240

Group type: EXPERIMENTAL
Intervention: Morphine 1 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3799504

Group type: EXPERIMENTAL
Intervention: PUFA diet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LO diet
Number of subjects: 6
Study: 29486772

Group type: EXPERIMENTAL
Intervention: Beverages containing bilberry
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beverages containing blackcurrant
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beverages containing mango
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beverages containing rose hip
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (glucose drink)
Number of subjects: 11
Study: 27473868

Group type: EXPERIMENTAL
Intervention: Guidewire exchange (GWE)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Venipuncture insertion (VPI)
Number of subjects: 178
Study: 25711332

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 424

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 424
Study: 23415190

Group type: EXPERIMENTAL
Intervention: Family-centered, primary care-based intervention involving 6 weeks of interactive group classes followed by 6 months of culturally sensitive monthly coaching
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 41
Study: 20522410

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 82
Study: 19544679

Group type: EXPERIMENTAL
Intervention: CYP3A4-metabolized statins (atorvastatin)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Partially-CYP3A4-metabolized statins (simvastatin)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Statin naive patients
Number of subjects: 3
Study: 16635205

Group type: EXPERIMENTAL
Intervention: Patient-collected vaginal swabs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provider-collected specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two swabs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two wicks
Number of subjects: 0
Study: 15871555

Group type: COMPARATOR
Intervention: Insulin aspart (NovoLog, NovoRapid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biphasic insulin aspart (BIAsp30)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BIAsp30
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin aspart or BIAsp30
Number of subjects: 0
Study: 10933570

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 to 300 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Atenolol 25 to 150 mg
Number of subjects: 54
Study: 9192124

Group type: EXPERIMENTAL
Intervention: celiprolol 200 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 7901342

Group type: EXPERIMENTAL
Intervention: Paclitaxel high dose (175 mg/m2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel low dose (135 mg/m2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 3-hour infusion schedule
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 24-hour infusion schedule
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel (all treatment arms)
Number of subjects: 18
Study: 3484922

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mesocaval shunt (MS)
Number of subjects: 80
Study: 31397647

Group type: EXPERIMENTAL
Intervention: Structured program of exercise training (walking, aerobic, strength-conditioning, relaxation exercises) during pregnancy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no structured exercise intervention)
Number of subjects: 170
Study: 30360881

Group type: EXPERIMENTAL
Intervention: Fatty fish (n=114)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Meat (n=118)
Number of subjects: 232
Study: 26951702

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration directly from the cardiology unit at each monitoring visit
Number of subjects: 784

Group type: COMPARATOR
Intervention: Standard retail pharmacy channel prescription
Number of subjects: 784
Study: 25016276

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) and General exercises
Number of subjects: 54

Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 54
Study: 22430920

Group type: EXPERIMENTAL
Intervention: Colchicine (1.0–2.0 mg on the first day, followed by 0.5–1.0 mg/day for 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Colchicine and Placebo
Number of subjects: 120
Study: 19633042

Group type: EXPERIMENTAL
Intervention: High-dose adecatumumab (6 mg/kg every two weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Low-dose adecatumumab (2 mg/kg every two weeks)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High-dose adecatumumab
Number of subjects: 109

Group type: COMPARATOR
Intervention: Low-dose adecatumumab
Number of subjects: 109
Study: 18493207

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (for children >=20 kg)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (for children >=20 kg)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Esomeprazole (all doses)
Number of subjects: 109
Study: 15931231

Group type: EXPERIMENTAL
Intervention: 150 mg/day IL-1ra
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 12595860

Group type: EXPERIMENTAL
Intervention: NIR stent (second-generation stainless steel stent)
Number of subjects: 424

Group type: COMPARATOR
Intervention: PS stent (first-generation Palmaz-Schatz stent)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: NIR stent
Number of subjects: 424

Group type: COMPARATOR
Intervention: PS stent
Number of subjects: 424
Study: 10532204

Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation (ECC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Surgical intervention (control group B)
Number of subjects: 25
Study: 8679463

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide)
Number of subjects: 441

Group type: COMPARATOR
Intervention: No perioperative chemotherapy
Number of subjects: 441
Study: 1563329

Group type: EXPERIMENTAL
Intervention: Muesli (slow release starch: SRS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cornflakes (fast release starch: FRS)
Number of subjects: 14
Study: 3913726

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (doses between 12.5 and 300 mg)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Codeine sulfate (60 mg)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study: 31164602

Group type: EXPERIMENTAL
Intervention: School-Based Sexual and Reproductive Health (SBSRH) interventions including tailored SRH information, in-school medical care, and referral over 12 months.
Number of subjects: 1080

Group type: COMPARATOR
Intervention: No intervention from the research team (control group).
Number of subjects: 1080
Study: 29238974

Group type: EXPERIMENTAL
Intervention: DEE (docetaxel, epirubicin, and rh-endostatin)
Number of subjects: 803

Group type: COMPARATOR
Intervention: DE (docetaxel and epirubicin)
Number of subjects: 803
Study: 27431042

Group type: EXPERIMENTAL
Intervention: MIA: STEP
Number of subjects: 450

Group type: COMPARATOR
Intervention: SAU
Number of subjects: 450
Study: 23106157

Group type: EXPERIMENTAL
Intervention: Intradermal injection of 1.5 mL (250 MU) of BTX‐A
Number of subjects: 11

Group type: COMPARATOR
Intervention: Iontophoresis of BTX‐A
Number of subjects: 11
Study: 22296885

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (OMACOR fish oil, 850-882 mg eicosapentaenoic and docosahexaenoic acid)
Number of subjects: 150
Study: 21434529

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN‐alpha2a) 5 MU/m2 to 10 MU/m2 for six months and lamivudine (4 mg/kg/day)
Number of subjects: 38
Study: 18025857

Group type: EXPERIMENTAL
Intervention: Lithotomy position (LP)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Left lateral decubitis position (LLDP)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Group 3 (LP and LLDP)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Group 4 (LLDP and LP)
Number of subjects: 340
Study: 15755593

Group type: EXPERIMENTAL
Intervention: MeNZB™ vaccine
Number of subjects: 4
Study: 12126287

Group type: EXPERIMENTAL
Intervention: Bupropion for smoking cessation (exact dosage and duration not specified)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Non-randomized participants (control group)
Number of subjects: 66
Study: 11593579

Group type: EXPERIMENTAL
Intervention: Surgery with postoperative radiotherapy (16 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Surgery alone (13 patients)
Number of subjects: 29
Study: 8523110

Group type: EXPERIMENTAL
Intervention: 125I-chimeric 17-1A antibody, administered in doses of 20, 40, 60, 80, 100, 150, 200, or 250 mCi, with infusions at 4-day intervals.
Number of subjects: 28
Study: 1842236

Group type: EXPERIMENTAL
Intervention: Butter and milk diet (300 mg cholesterol and 95 g fat)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single egg diet (300 mg cholesterol and 6 g fat)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Crystalline cholesterol with 200 ml milk (1020 mg cholesterol and 14 g fat)
Number of subjects: 24
Study: 7183209

Group type: EXPERIMENTAL
Intervention: Acupuncture at traditional loci (right side GB-20, both sides EH-6, both sides St-36)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture at non-acupuncture loci (self-control study)
Number of subjects: 40
Study: 31778630

Group type: EXPERIMENTAL
Intervention: Low tidal volume (6 mL/kg predicted body weight)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Conventional tidal volume (10 mL/kg predicted body weight)
Number of subjects: 1240
Study: 29701662

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing 10 billion Lactobacillus casei, administered as two bottles daily via feeding tube.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified what the control was).
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing 10 billion Lactobacillus casei.
Number of subjects: 32
Study: 26418784

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Comparison of upper and lower forehead VAS scores
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Overall comparison of BTX‐A vs control
Number of subjects: 26
Study: 24439982

Group type: EXPERIMENTAL
Intervention: Epoprostenol with arginine and sucrose excipients (Veletri)
Number of subjects: 41
Study: 22920991

Group type: COMPARATOR
Intervention: Standard Care (brief advice to quit smoking, nicotine replacement therapy, self-help materials)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Enhanced Care (standard care plus cell phone-delivered text/graphical messaging)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Intensive Care (enhanced care plus 11 proactive counseling sessions via cell phone)
Number of subjects: 756
Study: 20207829

Group type: EXPERIMENTAL
Intervention: IGF‐I target of 2 SDS (IGF2T)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: IGF‐I target of 0 SDS (IGF0T)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional weight‐based GH dosing of 40 microg/kg x d (Conv)
Number of subjects: 165
Study: 17673873

Group type: EXPERIMENTAL
Intervention: LVEDP >30 mm Hg (n=187)
Number of subjects: 744

Group type: COMPARATOR
Intervention: Other cohorts combined (n=603)
Number of subjects: 744
Study: 15670485

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 11893636

Group type: EXPERIMENTAL
Intervention: Iodixanol (150 mgI ml(‐1) and 320 mgI ml(‐1))
Number of subjects: 154

Group type: COMPARATOR
Intervention: Iohexol (140 mgI ml(‐1) and 300 mgI ml(‐1))
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 154

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 154
Study: 9527073

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 410

Group type: COMPARATOR
Intervention: Beta blockers, calcium antagonists, or nitrates
Number of subjects: 410
Study: 7843454

Group type: EXPERIMENTAL
Intervention: Five milliliters of 2% mepivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 45
Study: 2142858

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 5 ng.kg‐1.min‐1, n = 9
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (isotonic saline, n = 7)
Number of subjects: 16
Study: 455981

Group type: EXPERIMENTAL
Intervention: Paper formulation of oral contraceptive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional tablet
Number of subjects: 0
Study: 31841744

Group type: EXPERIMENTAL
Intervention: HPD-BCX (energy-restricted HPD + BCX)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (standard energy-restricted diet + placebo)
Number of subjects: 92
Study: 30685287

Group type: EXPERIMENTAL
Intervention: Complete CHOICE
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Enhanced Care
Number of subjects: 1008
Study: 27967294

Group type: EXPERIMENTAL
Intervention: Myeloid growth factors (GF) administered to 256 patients (49%)
Number of subjects: 520

Group type: COMPARATOR
Intervention: CHOP or R‐CHOP treatment
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Risk factors for FN
Number of subjects: 520
Study: 26351990

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 3

Group type: COMPARATOR
Intervention: Prolonged institutional rearing (control)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Never-institutionalized children (control)
Number of subjects: 3
Study: 24089542

Group type: EXPERIMENTAL
Intervention: Jet injection of insulin aspart
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional insulin pen
Number of subjects: 24
Study: 19775782

Group type: EXPERIMENTAL
Intervention: EP group (diet and physical activity education from 16 gestational weeks to six months post partum)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: EPP group (diet and physical activity education from 24-48 hours after birth to six months post partum)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Comparison group (routine outpatient department obstetric educational programme)
Number of subjects: 189
Study: 19267286

Group type: EXPERIMENTAL
Intervention: Water drinking at a rate of 10 ml/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrient liquid drinking at a rate of 100 ml/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrient liquid drinking at a rate of 20 ml/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow nutrient drinking
Number of subjects: 0
Study: 16700685

Group type: EXPERIMENTAL
Intervention: Guided Participation (GP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard Care Teaching
Number of subjects: 16
Study: 15612345

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate adhesive debonded within 30 minutes after bonding
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate adhesive debonded after 24 hours immersion in deionized water at 37 degrees C
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cyanoacrylate adhesive debonded after 30 days immersion in deionized water at 37 degrees C
Number of subjects: 60
Study: 12439363

Group type: EXPERIMENTAL
Intervention: Preprocedural hydration, amount of dye administered, and postprocedural therapies
Number of subjects: 0